Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation

References

• World Health Organization Study GroupAssessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study GroupWorld Health Organ Tech Rep Ser199484311297941614
   PubMed Web of Science ®Google Scholar
• NguyenNDAhlborgHGCenterJREismanJANguyenTVResidual lifetime risk of fractures in women and menJ Bone Miner Res200722678178817352657
   PubMed Web of Science ®Google Scholar
• JohnellOKanisJAAn estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporos Int200617121726173316983459
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDEEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA199828024207720829875874
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupJAMA1999282141344135210527181
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPDEffect of risedronate on the risk of hip fracture in elderly women. HIP Intervention Program Study GroupN Engl J Med2001344533334011172164
   PubMed Web of Science ®Google Scholar
• ChesnutCHIIISkagAChristiansenCEffects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res20041981241124915231010
   PubMed Web of Science ®Google Scholar
• CranneyATugwellPAdachiJIII. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosisEndocr Rev200223451752312202466
   PubMed Web of Science ®Google Scholar
• ReginsterJMinneHWSorensenOHRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int2000111839110663363
   PubMed Web of Science ®Google Scholar
• MellstromDDSorensenOHGoemaereSRouxCJohnsonTDChinesAASeven years of treatment with risedronate in women with postmenopausal osteoporosisCalcif Tissue Int200475846246815455188
   PubMed Web of Science ®Google Scholar
• CranneyAAdachiJDGuyattGRisedronate for the prevention and treatment of postmenopausal osteoporosisCochrane Database Syst Rev20081CD00452318254053
   PubMed Web of Science ®Google Scholar
• CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
   PubMed Web of Science ®Google Scholar
• CompstonJEBisphosphonates and atypical femoral fractures: a time for reflectionMaturitas20106513419932574
   PubMed Web of Science ®Google Scholar
• EttingerBPressmanAScheinJChanJSilverPConnollyNAlendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuationJ Manag Care Pharm199845488492
   Google Scholar
• Warner ChilcottActonel^® prescribing information22011 Available from: http://actonel.com/global/prescribing_information.pdfAccessed December 28, 2011
   Google Scholar
• TaggartHBologneseMALindsayRUpper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trialsMayo Clin Proc200277326227011888030
   PubMed Web of Science ®Google Scholar
• BrownJPKendlerDLMcClungMRThe efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosisCalcif Tissue Int200271210311112085156
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBLiZChinesAAHanleyDABrownJPTwo-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosisCurr Med Res Opin200420575776415140343
   PubMed Web of Science ®Google Scholar
• CramerJAGoldDTSilvermanSLLewieckiEMA systematic review of persistence and compliance with bisphosphonates for osteoporosisOsteoporos Int20071881023103117308956
   PubMed Web of Science ®Google Scholar
• ReckerRRGallagherRMacCosbePEEffect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of womenMayo Clin Proc200580785686116007889
   PubMed Web of Science ®Google Scholar
• DelmasPDBenhamouCLManZMonthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety resultsOsteoporos Int20081971039104518087660
   PubMed Web of Science ®Google Scholar
• RacewiczAJSchofieldPJCahallDLClineGABurgioDEMonthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot studyCurr Med Res Opin200723123079308917971285
   PubMed Web of Science ®Google Scholar
• Ste-MarieLGBrownJPBearyJFComparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging studyClin Ther200931227228519302900
   PubMed Web of Science ®Google Scholar
• DelmasPDMcClungMRZanchettaJREfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisBone2008421364217920005
   PubMed Web of Science ®Google Scholar
• HalpernRBeckerLIqbalSUKazisLEMacariosDBadamgaravEThe association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosisJ Manag Care Pharm2011171253921204588
   PubMed Web of Science ®Google Scholar
• HadjiPClausVZillerVIntorciaMKostevKSteinleTGRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonatesOsteoporos Int201223122323121308365
   PubMed Web of Science ®Google Scholar
• EastellRVrijensBCahallDLRingeJDGarneroPWattsNBBone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherenceJ Bone Miner Res20112671662166921312265
   PubMed Web of Science ®Google Scholar
• CaroJJIshakKJHuybrechtsKFRaggioGNaujoksCThe impact of compliance with osteoporosis therapy on fracture rates in actual practiceOsteoporos Int200415121003100815167989
   PubMed Web of Science ®Google Scholar
• BarrettJWorthEBaussFEpsteinSIbandronate: a clinical pharmacological and pharmacokinetic updateJ Clin Pharmacol200444995196515317823
   PubMed Web of Science ®Google Scholar
• OguraYGonshoACyongJCOrimoHClinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorptionJ Bone Miner Metab200422212012614999522
   PubMed Web of Science ®Google Scholar
• AgrawalSKruegerDCEngelkeJABetween-meal risedronate does not alter bone turnover in nursing home residentsJ Am Geriatr Soc200654579079516696745
   PubMed Web of Science ®Google Scholar
• KendlerDLRingeJDSte-MarieLGVrijensBTaylorEBDelmasPDRisedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosisOsteoporos Int200920111895190219296144
   PubMed Web of Science ®Google Scholar
• HamdyRCZoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massDrug Des Devel Ther20104321335
   Web of Science ®Google Scholar
• McClungMRMillerPDBrownJPEfficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tabletOsteoporos Int201223126727621947137
   PubMed Web of Science ®Google Scholar
• RingeJDFarahmandPFaberHDorstASustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year studyRheumatol Int200929331131518762944
   PubMed Web of Science ®Google Scholar
• BoonenSOrwollESWenderothDStonerKJEusebioRDelmasPDOnce-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter studyJ Bone Miner Res200924471972519049326
   PubMed Web of Science ®Google Scholar
• RackoffPEfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisClin Interv Aging2009420721419503783
   PubMed Web of Science ®Google Scholar
• CasadeiKBeckerCOnce-monthly risedronate for postmenopausal osteoporosisInt J Womens Health201011921072270
   PubMedGoogle Scholar
• Moro-AlvarezMJDiaz-CurielMRisedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosisClin Interv Aging20083222723218686745
   PubMed Web of Science ®Google Scholar
• MartinKEYuJCampbellHEAbarcaJWhiteTJAnalysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause costJ Manag Care Pharm201117859660921942301
   PubMed Web of Science ®Google Scholar
• TostesonANBurgeRTMarshallDALindsayRTherapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerationsAm J Manag Care200814960561518778176
   PubMed Web of Science ®Google Scholar
• WhiteHJBettiolSSPereraRRobertsNWJavaidMKFarmerAJA systematic review assessing the effectiveness of interventions to improve persistence with anti-resorptive therapy in women at high risk of clinical fractureFam Pract201027659360320693238
   PubMed Web of Science ®Google Scholar